Literature DB >> 128306

Sch 1000: a new anticholinergic bronchodilator.

M J Gross.   

Abstract

Sch 1000 is a derivative of atropine with equivalent bronchodilator activity. A double blind controlled study of Sch 1000 administered to asthmatic subjects by inhalation in 4 doses from 10 mug to 80 mug was conducted. The onset of action was between 15 and 30 min, compared to 5 min for isoproterenol, but persisted for 4 hours compared to 1 hour for isoproterenol. The maximal level of bronchodilatation produced by Sch 1000 was comparable to but not as great as that after isoproterenol. Dose-response data suggested that maximal bronchodilatation may be achieved by 10 to 20 mug of Sch 1000; larger doses did not result in significantly greater increases in forced expiratory volume in 1 sec or maximal mid-expiratory flow. The Sch 1000-mediated increase in maximal mid-expiratory flow was significantly greater than that of forced expiratory volume in 1 sec. Fewer side effects were encountered after Sch 1000 than after isoproterenol and no atropine-like effects could be attributed to Sch 1000 in the doses studied.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 128306     DOI: 10.1164/arrd.1975.112.6.823

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  12 in total

1.  Ipratropium bromide (Sch 1000) monohydrate aerosol: bronchodilator effect of three dose levels in asthmatics.

Authors:  R E Ruffin; M T Newhouse
Journal:  Lung       Date:  1978       Impact factor: 2.584

2.  LTD4-induced bronchoconstriction in patients with asthma: lack of a vagal reflex.

Authors:  L E Ayala; N B Choudry; R W Fuller
Journal:  Br J Clin Pharmacol       Date:  1988-07       Impact factor: 4.335

3.  Ipratropium bromide in children with asthma.

Authors:  N P Mann; E J Hiller
Journal:  Thorax       Date:  1982-01       Impact factor: 9.139

4.  Treatment of adult asthma: controlled double-blind clinical trial of oxitropium bromide.

Authors:  A Taytard; J Auzerie; J Vergeret; N Tozon; P Freour
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 5.  Anticholinergic agents for chronic asthma in adults.

Authors:  M Westby; M Benson; P Gibson
Journal:  Cochrane Database Syst Rev       Date:  2004

Review 6.  Chronic obstructive pulmonary disease.

Authors:  N R Anthonisen
Journal:  CMAJ       Date:  1988-03-15       Impact factor: 8.262

7.  Response to aerosol salbutamol, SCH 1000, and placebo in cystic fibrosis.

Authors:  M Kattan; A Mansell; H Levison; M Corey; I R Krastins
Journal:  Thorax       Date:  1980-07       Impact factor: 9.139

Review 8.  Ipratropium bromide: a review of its pharmacological properties and therapeutic efficacy in asthma and chronic bronchitis.

Authors:  G E Pakes; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-10       Impact factor: 9.546

9.  A single dose comparison of a combination of fenoterol and ipratropium aerosols in bronchial asthma.

Authors:  P Lawford; K N Palmer
Journal:  Postgrad Med J       Date:  1983-01       Impact factor: 2.401

10.  Effect of four weeks' high dose ipratropium bromide treatment on lung mucociliary clearance.

Authors:  R G Taylor; D Pavia; J E Agnew; M T Lopez-Vidriero; S P Newman; T Lennard-Jones; S W Clarke
Journal:  Thorax       Date:  1986-04       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.